Candesartan in the Prevention of Relapsing Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00130975
Recruitment Status : Completed
First Posted : August 17, 2005
Last Update Posted : January 4, 2007
Helse Ost
Ullevaal University Hospital
Information provided by:
Asker & Baerum Hospital

Brief Summary:
The purpose of this study is to test the hypothesis that treatment with the angiotensin II type 1 receptor antagonist candesartan may reduce the recurrence rate of atrial fibrillation after electrical cardioversion.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Drug: Candesartan Phase 3

Detailed Description:

Background: The most effective procedure to restore sinus rhythm in patients with persistent atrial fibrillation (AF) is electrical cardioversion, but AF recurs in 60-80% of the patients during the first year. AF is associated with electrical and anatomical remodelling of the atria, and angiotensin II is involved in the remodelling process. Studies have indicated that the angiotensin II type 1 receptor antagonist candesartan may counteract both electrical and anatomical remodelling induced by AF. The investigators therefore hypothesised that treatment with candesartan may reduce the recurrence rate of AF after electrical cardioversion.

Study design: 171 patients with persistent AF scheduled for electrical cardioversion are randomised in a double blind, placebo-controlled study. The patients receive tablets of candesartan 8 mg or matching placebo once daily for 3-6 weeks before cardioversion, and candesartan 16 mg or matching placebo once daily for 6 months after cardioversion. The study medication is discontinued if electrical cardioversion is unsuccessful or if AF recurrence is documented. Primary endpoint is recurrence of AF. Clinical, electrocardiographic, echocardiographic and biochemical markers will be analysed.

Study Type : Interventional  (Clinical Trial)
Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : April 2001
Study Completion Date : September 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Recurrence of atrial fibrillation

Secondary Outcome Measures :
  1. Time to recurrence of atrial fibrillation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with atrial fibrillation, diagnosed electrocardiographically, of more than 48 hours duration in whom direct current (DC) cardioversion is planned.

Exclusion Criteria:

  • Patients with a history of known hypersensitivity or contraindication to any angiotensin II receptor blocker or any angiotensin-converting enzyme (ACE) inhibitor.
  • Patients currently receiving an ACE inhibitor or angiotensin II antagonist because of heart failure or other strong indication.
  • Patients currently receiving any antiarrhythmic medication including sotalol. Other beta-blockers will not be regarded as specific antiarrhythmic agents.
  • Significant renal artery stenosis and any medical condition in which administration of a vasodilator is contraindicated; serum creatinine > 225 micromol/L; or serum potassium > 5.5 mmol/L; or serum sodium < 128 mmol/L.
  • Patients with severe hepatic dysfunction.
  • Life-limiting disease or substance abuse which may affect participation.
  • Patients unwilling to participate.
  • Patients who have previously undergone DC cardioversion for atrial fibrillation within the last month.
  • Thyrotoxicosis.
  • Patients with a systolic blood pressure of < 100 mm Hg.
  • Hypertensive patients requiring intensified treatment prior to DC cardioversion.
  • Pregnancy or lactation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00130975

Ulleval University Hospital
Oslo, Norway, 0407
Asker & Baerum Hospital
Rud, Norway, 1309
Sponsors and Collaborators
Asker & Baerum Hospital
Helse Ost
Ullevaal University Hospital
Principal Investigator: Arnljot Tveit, MD Asker & Baerum Hospital

Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00130975     History of Changes
Other Study ID Numbers: CAPRAF
First Posted: August 17, 2005    Key Record Dates
Last Update Posted: January 4, 2007
Last Verified: January 2007

Keywords provided by Asker & Baerum Hospital:
Atrial fibrillation.

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Candesartan cilexetil
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action